GlaxoSmithKline announced that Tanzeum (albiglutide) subcutaneous injection is now available for the treatment of type 2 diabetes in adults as adjunct to diet and exercise.

Tanzeum, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a once weekly treatment indicated for use in combination with other antidiabetic medications. It has been approved with a Risk Evauation and Mitigation Strategy (REMS) to ensure that the benefits outweigh the potential risk of medullary thyroid carcinoma and the risk of acute pancreatitis.

RELATED: New Diabetes Treatment Gets FDA Approval

Tanzeum for subcutaneous injection is available as a 30mg or 50mg single-dose Pen in 4-count cartons.

For more information call (888) 825-5249 or visit